IMPAACT 2036
Phase I/II Study of the Safety, Tolerability, Pharmacokinetics, and antiviral activity of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed HIV-Infected
Co-HED
This trial aims to assess the effects of co-administration of Highly Active Anti-retroviral therapy (HAART) and Antiepileptic drugs on
P1115
A multi-centre phase I/II proof-of-concept clinical trial exploring the effects of early intensive antiretroviral therapy (ART) on achieving HIV remission in neonates. Started in June 2015 at Baylor-Uganda’s Centre of […]
